ArticleBMC cancer2025
Deep learning-based computational approach for predicting ncRNAs-disease associations in metaplastic breast cancer diagnosis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Exploring the Clinical Landscape of Long Non-coding RNAs in Cancer Diagnosis and Therapy.Biochemical genetics · 2026Review
- In-Silico identification and optimization of therapeutic peptides against breast cancer via transcriptomic profiling.Molecular diversity · 2026Article
- Harnessing Deep Learning Models for Guide RNA Optimization and Off-Target Prediction in CRISPR Systems.Biotechnology journal · 2026Review
- CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review.Acta neurologica Belgica · 2026Review
- Hybrid tuned deep learning model for breast cancer diagnosis using genetic data.Scientific reports · 2026Article
- Mechanisms of Action and Biomarker Potential of ncRNAs in Hepatocellular Carcinoma and Liver Fibrosis: A Review.Analytical cellular pathology (Amsterdam) · 2026Review
- Computational identification and validation of non-coding rna biomarkers in gastrointestinal cancer.Functional & integrative genomics · 2025Review
- Gut microbiome dysbiosis and antimicrobial resistance in the Middle East: a converging public health crisis in conflict and fragile settings.Archives of microbiology · 2025Review
- Spinal Cord Injury 2.0: Bridging the Gap Between Neurobiology, Technology, and Hope in the Era of Precision Medicine.Stem cell reviews and reports · 2025Review
- Next-generation oncology: integrative therapeutic frontiers at the crossroads of precision genomics, immuno-engineering, and tumor microenvironment modulation.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-coding RNAs (ncRNAs) play a crucial role in breast cancer progression, necessitating advanced computational approaches for precise disease classification. This study introduces a Deep Reinforcement Learning (DRL)-based framework for predicting ncRNA-disease associations in metaplastic breast cancer (MBC) using a multi-dimensional descriptor system (ncRNADS) integrating 550 sequence-based features and 1,150 target gene descriptors (miRDB score ≥ 90). The model achieved 96.20% accuracy, 96.48% precision, 96.10% recall, and a 96.29% F1-score, outperforming traditional classifiers such as support vector machines (SVM) and neural networks. Feature selection and optimization reduced dimensionality by 42.5% (4,430 to 2,545 features) while maintaining high accuracy, demonstrating computational efficiency. External validation confirmed model specificity to breast cancer subtypes (87-96.5% accuracy) and minimal cross-reactivity with unrelated diseases like Alzheimer's (8-9% accuracy), ensuring robustness. SHAP analysis identified key sequence motifs (e.g., "UUG") and structural free energy (ΔG = - 12.3 kcal/mol) as critical predictors, validated by PCA (82% variance) and t-SNE clustering. Survival analysis using TCGA data revealed prognostic significance for MALAT1, HOTAIR, and NEAT1 (associated with poor survival, HR = 1.76-2.71) and GAS5 (protective effect, HR = 0.60). The DRL model demonstrated rapid training (0.08 s/epoch) and cloud deployment compatibility, underscoring its scalability for large-scale applications. These findings establish ncRNA-driven classification as a cornerstone for precision oncology, enabling patient stratification, survival prediction, and therapeutic target identification in MBC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.